News
Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial … ...
April 29, 2024 05:53 PM EDT Updated 06:48 PM ...
Senate Finance Committee Chair Ron Wyden (D-OR) is urging HHS to take a stronger stance on healthcare companies' cybersecurity practices as the healthcare system is still piecing together what ...
Bristol Myers Squibb said its KRAS cancer drug Krazati met the primary endpoint in a Phase 3 confirmatory trial in patients with non-small cell lung cancer, according to new data ...
Madrigal Pharmaceuticals is “making great progress” on the rollout of its NASH drug Rezdiffra, executives said less than a month post-launch. Rezdiffra was ...
Pacific Biosciences, or PacBio for short, made its name in long-read DNA sequencing — the technology recently used to sequence the entire human genome — filling in a ...
In the days following the US Supreme Court’s rollback of federal abortion rights, more than 100 women biotech executives came together in an ...
Up until recently, Alban de La Sablière was Sanofi ’s chief dealmaker, reporting directly to CEO Paul Hudson without officially being a C-suite executive ...
The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...
Tech, commerce-focused investor unveils $500M bet on healthcare ...
CVS Health is shutting down the clinical trials business that it launched just two years ago, part of an effort to focus on its core … ...
The FDA is hoping its latest solution will stave off the continued shortage of cisplatin, a key drug used in treating several types of cancer. Beginning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results